TABLE 1

Biodistribution of 124I-PIB-ZHER2:342 and 125I-PIB-Trastuzumab After Injection in BALB/C nu/nu Mice Bearing HER2-Expressing NCI-N87 Xenografts

Biodistribution
Location6 h24 h72 h
124I-PIB-ZHER2:342
 Blood0.59 ± 0.050.09 ± 0.020.021 ± 0.008
 Lung0.8 ± 0.20.5 ± 0.10.2 ± 0.1
 Liver0.84 ± 0.090.20 ± 0.070.077 ± 0.008
 Spleen0.9 ± 0.20.4 ± 0.20.18 ± 0.05
 Stomach1 ± 10.32 ± 0.090.14 ± 0.07
 Kidney3.2 ± 0.40.19 ± 0.010.11 ± 0.02
 Salivary gland0.8 ± 0.3NMNM
 Thyroid*0.2 ± 0.2NMNM
 Tumor4.7 ± 1.01.4 ± 0.30.4 ± 0.1
 Muscle0.10 ± 0.05NMNM
 Intestines with content*1.3 ± 0.220.07 ± 0.010.05 ± 0.02
 Carcass*2.4 ± 0.10.7 ± 0.10.17 ± 0.02
125I-PIB-trastuzumab
 Blood18 ± 313 ± 29 ± 2
 Lung6.5 ± 1.05. 6 ± 0.93.3 ± 0.6
 Liver4.7 ± 0.33.1 ± 0.61.9 ± 0.6
 Spleen6 ± 15 ± 21.8 ± 0.6
 Stomach1.5 ± 0.61.3 ± 0.40.8 ± 0.3
 Kidney6.5 ± 1.05.1 ± 0.33.0 ± 0.5
 Salivary gland2.3 ± 0.42.8 ± 0.51.7 ± 0.5
 Thyroid*0.08 ± 0.020.16 ± 0.060.041 ± 0.006
 Tumor14 ± 716 ± 312 ± 3
 Muscle0.7 ± 0.11.3 ± 0.10.62 ± 0.08
 Intestines with content*4.0 ± 0.62.7 ± 0.21.7 ± 0.4
 Carcass*20 ± 321.0 ± 0.715 ± 4
  • * Data for thyroid, intestines with content, and carcass are given as %IA per whole sample.

  • NM = nonmeasurable (counts per sample were less than 2 times background counts).

  • Data are presented as an average %IA/g and SD (n = 4).